Links to articles in the current and previous 2 issues of this bulletin are displayed below.
To receive email notifications about new issues of this bulletin, please email: richard.fallis@healthcarelibrary.qub.ac.uk
Advancing personalised care in ovarian cancer using CT and MRI radiomics
Cancer of unknown primary site
Cancer-related stigmatization, quality of life, and fear of death among newly diagnosed cancer patients
Chronic myeloid leukemia: a review (JAMA)
Demoralization syndrome in end-of-life cancer patients: a qualitative study
Diabetes can impact cellular immunity in solid tumors
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (new NICE guideline TA1064)
Enhanced CAR T-cell therapy for lymphoma after previous failure
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (new NICE guideline TA1062)
Gardening initiatives as an approach to cancer prevention for children and youth
Gastric cancer (Lancet seminar review)
Inflammatory breast cancer response to modern neoadjuvant chemotherapy
Lymphadenectomy or sentinel node biopsy for the management of endometrial cancer (new Cochrane intervention review)
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer (PARTNER)
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (new NICE guideline TA1065)
Ph-positive acute lymphoblastic leukemia — 25 years of progress
Preventive medication deprescribing in advanced cancer patients approaching end of life
Prostate cancer: a review (JAMA)
Small cell lung cancer: a review (JAMA)
Suspected cancer: recognition and referral (updated NICE guideline NG12)
Vaccines for preventing infections in adults with haematological malignancies (new Cochrane intervention review)
Yoga for fatigue in people with cancer (new Cochrane intervention review)
American Journal of Hospice & Palliative Medicine (Jun); American Journal of Surgery, The (May); Clinical Radiology (May); Cochrane Library (May-Jun); Internal Medicine Journal (Apr); JAMA (Apr-May); Lancet, The (May-Jun); Nature Communications (May); NEJM (May); NICE website (May-Jun); Omega (Jun); Public Health (May); Trends in Immunology (Apr)
Advances in the management of endometrial cancer
Assessment of a polygenic risk score in screening for prostate cancer
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia (new NICE guideline TA1049)
Fear of the cancer coming back: a metasynthesis of fear of recurrence in breast cancer
Intra-tumoral bacteria in breast cancer and intervention strategies
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable (new NICE guideline TA1048)
Lymphatic transport in anti-tumor immunity and metastasis
Multimodal interventions for cachexia management (new Cochrane intervention review)
Next‐generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer (new Cochrane intervention review)
Pancreatic cancer (Lancet review)
Positron emission tomography‐adapted therapy for first‐line treatment in adults with Hodgkin lymphoma (new Cochrane intervention review)
Racial disparities in thyroid cancer outcomes: a systematic review
Testicular germ cell tumors: a review
Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (new NICE guideline TA1046)
Advanced Drug Delivery Reviews (Feb); American Journal of Surgery (Feb); BMJ, The (Mar); Cochrane Library (Mar-Apr); JAMA (Mar); JAMA Otolaryngology - Head & Neck Surgery (Feb); Journal of Experimental Medicine (Feb); NEJM (Apr); NICE website (Mar); Obesity (Mar); Public Health (Jan); Public Health Nursing (Jan/Feb)
Advanced breast cancer: diagnosis and treatment (updated NICE guideline CG81)
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours (new NICE guideline TA1034)
Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment (updated NICE guideline HTE12)
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (new NICE guideline TA1030)
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (new NICE guideline TA1041)
Early and locally advanced breast cancer: diagnosis and management (updated NICE guideline NG101)
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment (new NICE guideline TA1036)
Home hospitalization in palliative care for advanced cancer and dementia: a systematic review
Imaging in diagnosis and active surveillance for prostate cancer: a review
Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer (updated Cochrane intervention review)
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (new NICE guideline TA1040)
Ovarian cancer (updated NICE guideline QS18)
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (new NICE guideline TA1037)
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over (new NICE guideline TA1038)
Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over (new NICE guideline TA1039)
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (new NICE guideline TA1042)
Tebentafusp for treating advanced uveal melanoma (new NICE guideline IPG798)
Cochrane Library (Jan-Feb); JAMA Surgery (Jan); Journal of Pain and Symptom Management (Mar); Lancet, The (Jan); NICE website (Jan-Feb); Scientific Reports (Feb)
The Healthcare Library cannot guarantee the correctness or completeness of the information in these bulletins. The information is subject to change and we cannot guarantee it will remain up-to-date. It is your responsibility to check the accuracy and validity of the information. These bulletins are the property of the Healthcare Library; please credit us if re-using or distributing content from them.